SCHEMBL169770

SCHEMBL169770

Cc1ccc(CCC(=O)O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 11/20 0.79
KEAP1 Q14145 1/20 0.64
ALDH1A1 P00352 1/20 0.63
L3MBTL1 Q9Y468 2/20 0.61
TDP1 Q9NUW8 1/20 0.61
THRA P10827 1/20 0.57
THRB P10828 1/20 0.57
KMT2A Q03164 2/20 0.56
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
FFAR4 Q5NUL3 1/20 0.55
LMNA P02545 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27698271 0.98 FFAR1 (0.76) FFAR1KEAP1ALDH1A1L3MBTL1TDP1
SCHEMBL1510710 0.94 FFAR1 (0.71) FFAR1KEAP1ALDH1A1L3MBTL1TDP1
SCHEMBL19914066 0.89 FFAR1 (0.65) FFAR1KEAP1ALDH1A1L3MBTL1TDP1
SCHEMBL9495863 0.89 FFAR1 (0.65) FFAR1KEAP1ALDH1A1L3MBTL1TDP1
SCHEMBL12087474 0.89 FFAR1 (1.00) FFAR1FFAR4
SCHEMBL69746 0.88 FFAR1 (0.81) FFAR1KEAP1L3MBTL1CA1CA2
SCHEMBL764952 0.87 SMN1; SMN2 (0.67) FFAR1ALDH1A1L3MBTL1TDP1KMT2A
SCHEMBL7020238 0.86 FFAR1 (0.66) FFAR1KEAP1ALDH1A1L3MBTL1TDP1
Hydrochloric Acid SCHEMBL25264643 0.85 FFAR1 (0.77) FFAR1KEAP1L3MBTL1CA1CA2
SCHEMBL1066202 0.85 MAPT (0.66) FFAR1ALDH1A1L3MBTL1TDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 847 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
US-12304894-B2 Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11β-HSD1) PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) 2025-05-20 US claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO claimed
CN-117143097-A Beta-carbopol compound, preparation method thereof and application of beta-carbopol compound in resisting Alzheimer disease 中国人民解放军北部战区总医院 2023-12-01 CN claimed
US-20230047296-A1 Nrf2 REGULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-02-16 US claimed
US-20220194909-A1 DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11B-HSD1) PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) 2022-06-23 US claimed
CN-110167933-B As αVAzole amides and amines as integrin inhibitors 百时美施贵宝公司 2022-06-21 CN claimed
CN-112898137-A Preparation method and application of acetophenone derivative 安徽泽升科技有限公司 2021-06-04 CN claimed
WO-2020210922-A1 DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11Β-HSD1) PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE (CL) 2020-10-22 WO claimed
EP-3688124-A1 ESTER COMPOUNDS, LUBRICATING OIL COMPOSITIONS CONTAINING SAME AND PROCESSES FOR MAKING SAME ExxonMobil Chemical Patents Inc. (US) 2020-08-05 EP claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 US claimed
US-6893687-B2 Wetting with aqueous dispersion containing ultraviolet radiation crosslinkable resin, photoinitiator, corrosion inhibitor and wax; drying and curing without cracking or flaking CHEMETALL GMBH (DE) 2005-05-17 US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 US claimed
US-20040265964-A1 Inducers of recombinant protein expression IMMUNEX CORPORATION 2004-12-30 US claimed
WO-2004096833-A2 INDUCERS OF RECOMBINANT PROTEIN EXPRESSION IMMUNEX CORPORATION (US) 2004-11-11 WO claimed
US-20040022951-A1 Method for coating metallic surfaces and use of substrates coated in such a way or coatings produced in such a way CHEMETALL GMBH (DE) 2004-02-05 US claimed
US-20030185990-A1 Method for pretreating and coating metal surfaces prior to forming, with a paint-like coating and use of substrates so coated CHEMETALL GMBH (DE) 2003-10-02 US claimed
US-5006433-A Printing plate precursors for electrophotographic plate-making purposes FUJI PHOTO FILM CO., LTD. (JP) 1991-04-09 US claimed
EP-0012942-B1 ELECTROLYTIC PROCESS FOR PRODUCING BENZALDEHYDES BASF Aktiengesellschaft (DE) 1982-01-27 EP claimed
EP-0012942-A2 Electrolytic process for producing benzaldehydes BASF Aktiengesellschaft (DE) 1980-07-09 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220194909-A1 DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11B-HSD1) HSD11B1, HSD11B2, CYP11B1 FFAR1 695/4885KEAP1 1504/4885ALDH1A1 190/4885
US-20040265964-A1 Inducers of recombinant protein expression AADAC, CRYAA, PMAIP1 FFAR1 2596/4885KEAP1 4086/4885ALDH1A1 2178/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 FFAR1 3461/4885KEAP1 2845/4885ALDH1A1 1723/4885
US-20230047296-A1 Nrf2 REGULATORS NFE2L2, KEAP1, NQO1 FFAR1 823/4885KEAP1 2/4885ALDH1A1 621/4885
US-12304894-B2 Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11β-HSD1) HSD11B1, HSD11B2, HSD17B1 FFAR1 623/4885KEAP1 1272/4885ALDH1A1 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.